Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Janux Therapeutics, Inc. - Common Stock
(NQ:
JANX
)
14.12
-0.19 (-1.29%)
Streaming Delayed Price
Updated: 3:50 PM EST, Dec 26, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Janux Therapeutics, Inc. - Common Stock
< Previous
1
2
Next >
Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study
December 23, 2025
From
Janux Therapeutics
Via
Business Wire
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC
December 01, 2025
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC
November 24, 2025
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
November 06, 2025
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
August 07, 2025
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck
August 05, 2025
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day
July 24, 2025
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics to Host Virtual R&D Day on July 24, 2025
July 17, 2025
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer
May 15, 2025
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
May 08, 2025
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates
May 05, 2025
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
February 27, 2025
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
December 06, 2024
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
December 04, 2024
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Announces Proposed Public Offering
December 03, 2024
From
Janux Therapeutics
Via
Business Wire
Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC
December 02, 2024
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies
November 25, 2024
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
November 06, 2024
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
August 07, 2024
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Announces Updates to Board of Directors
July 22, 2024
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
May 07, 2024
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
March 08, 2024
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
February 29, 2024
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Announces Proposed Public Offering of Common Stock
February 27, 2024
From
Janux Therapeutics
Via
Business Wire
Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors
February 26, 2024
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008
February 20, 2024
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer
January 08, 2024
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
November 07, 2023
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
August 08, 2023
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
July 17, 2023
From
Janux Therapeutics
Via
Business Wire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
